Jennifer Goralski, MD, was first author on a paper published in the recent edition of The American Journal of Respiratory and Critical Care Medicine. Titled, “Phase 3 Open-Label Clinical Trial of Elexacaftor/Tezacaftor/Ivacaftor in Children Aged 2 Through 5 Years with Cystic Fibrosis and at Least One F508del Allele” it can be accessed via PubMed here. The paper proved the safety and efficacy of elexacaftor/tezacaftor/ivacaftor in children ages 2-5 years old with CF and the study was fundamental to FDA extension of the drug down to this age range. In the issue, Dr. Goralski was also cited as an “Emerging Investigator” by the Journal.